

antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Oral medicine

CAUTIONARY AND ADVISORY LABELS 2

▶ Trifluoperazine (Non-proprietary)

Trifluoperazine (as Trifluoperazine hydrochloride)

200 microgram per 1 ml Trifluoperazine 1mg/5ml oral solution sugar free sugar-free | 200 ml [PoM] £125.00 DT = £125.00

Trifluoperazine (as Trifluoperazine hydrochloride) 1 mg per 1 ml Trifluoperazine 5mg/5ml oral solution sugar free sugar-free | 150 ml [PoM] £30.00 DT = £29.25

Tablet

CAUTIONARY AND ADVISORY LABELS 2

▶ Trifluoperazine (Non-proprietary)

Trifluoperazine (as Trifluoperazine hydrochloride)

1 mg Trifluoperazine 1mg tablets | 112 tablet [PoM] £59.12-£99.80 DT = £59.12

Trifluoperazine (as Trifluoperazine hydrochloride)

5 mg Trifluoperazine 5mg tablets | 112 tablet [PoM] £134.89-£165.00 DT = £134.89

Zuclophenthixol

● INDICATIONS AND DOSE

Schizophrenia and other psychoses

▶ BY MOUTH

- Adult: Initially 20–30 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg), for debilitated patients, use elderly dose
- Elderly: Initially 5–15 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg)

- **CONTRA-INDICATIONS** Apathetic states · CNS depression · comatose states · phaeochromocytoma · withdrawn states

- **CAUTIONS** Hyperthyroidism · hypothyroidism

- **INTERACTIONS** → Appendix 1: zuclophenthixol

- **SIDE-EFFECTS** Anxiety · appetite abnormal · asthenia · concentration impaired · confusion · depression · diarrhoea · dyspnoea · eye disorders · fever · flatulence · gait abnormal · gastrointestinal discomfort · glucose tolerance impaired · headaches · hepatic disorders · hot flush · hyperacusia · hyperglycaemia · hyperhidrosis · hyperlipidaemia · hypersalivation · hypothermia · malaise · memory loss · muscle complaints · nasal congestion · nausea · neuromuscular dysfunction · pain · palpitations · paraesthesia · photosensitivity reaction · reflexes increased · seborrhoea · sexual dysfunction · skin reactions · sleep disorders · speech disorder · syncope · thirst · thrombocytopenia · tinnitus · urinary disorders · vertigo · vision disorders · vulvovaginal dryness · weight decreased · withdrawal syndrome

- **HEPATIC IMPAIRMENT** Manufacturer advises caution—monitor serum drug concentration.

Dose adjustments Manufacturer advises dose reduction of half the recommended dose.

- **RENAL IMPAIRMENT**

Dose adjustments Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Oral drops

▶ Ciatyl-Z (Imported (Germany))

Zuclophenthixol (as Zuclophenthixol dihydrochloride) 20 mg per 1 ml Ciatyl-Z 20mg/ml oral drops | 30 ml [PoM] 

Tablet

CAUTIONARY AND ADVISORY LABELS 2

▶ Clopixol (Lundbeck Ltd)

Zuclophenthixol (as Zuclophenthixol dihydrochloride) 2 mg Clopixol 2mg tablets | 100 tablet [PoM] £3.14 DT = £3.14

Zuclophenthixol (as Zuclophenthixol dihydrochloride)

10 mg Clopixol 10mg tablets | 100 tablet [PoM] £8.06 DT = £8.06

Zuclophenthixol (as Zuclophenthixol dihydrochloride)
25 mg Clopixol 25mg tablets | 100 tablet [PoM] £16.13 DT = £16.13

401

Zuclophenthixol acetate

20-Nov-2019

● INDICATIONS AND DOSE

Short-term management of acute psychosis | Short-term management of mania | Short-term management of exacerbation of chronic psychosis

▶ BY DEEP INTRAMUSCULAR INJECTION

- Adult: 50–150 mg, then 50–150 mg after 2–3 days if required, (1 additional dose may be needed 1–2 days after the first injection); maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections; maximum duration of treatment 2 weeks—if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclophenthixol acetate; to be administered into the gluteal muscle or lateral thigh
- Elderly: 50–100 mg, then 50–100 mg after 2–3 days if required, (1 additional dose may be needed 1–2 days after the first injection); maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections; maximum duration of treatment 2 weeks—if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclophenthixol acetate; to be administered into the gluteal muscle or lateral thigh

IMPORTANT SAFETY INFORMATION

When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is usually used in hospital for an *acute episode* and should **not** be confused with depot preparations which are usually used in the community or clinics for *maintenance* treatment.

SAFE PRACTICE

Zuclophenthixol acetate has been confused with zuclophenthixol decanoate; care must be taken to ensure the correct drug is prescribed and dispensed.

- **CONTRA-INDICATIONS** CNS depression · comatose states · phaeochromocytoma
- **CAUTIONS** Hyperthyroidism · hypothyroidism
- **INTERACTIONS** → Appendix 1: zuclophenthixol
- **SIDE-EFFECTS** Anxiety · appetite abnormal · asthenia · concentration impaired · confusion · depression · diarrhoea · dyspnoea · eye disorders · fever · flatulence · gait abnormal · gastrointestinal discomfort · glucose tolerance impaired · headaches · hepatic disorders · hot flush · hyperacusia · hyperglycaemia · hyperhidrosis · hyperlipidaemia · hypersalivation · hypothermia (dose-related) · malaise · memory loss · muscle complaints · nasal congestion · nausea · neuromuscular dysfunction · pain · palpitations · paraesthesia · photosensitivity reaction · reflexes increased · seborrhoea · sexual dysfunction · skin reactions · sleep disorders · speech disorder · syncope · thirst · thrombocytopenia · tinnitus · urinary disorders · vertigo · vision disorders · vulvovaginal dryness · weight decreased · withdrawal syndrome